{"id":"NCT01018186","sponsor":"GlaxoSmithKline","briefTitle":"Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study","officialTitle":"A Randomized, Double-Blind, Double Dummy, Active Comparator, Parallel Group, Multicenter Study to Evaluate the Safety of Once-Daily Fluticasone Furoate/GW642444 Inhalation Powder for 52 Weeks in Adolescent and Adult Subjects With Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10-19","primaryCompletion":"2011-05-01","completion":"2011-05-12","firstPosted":"2009-11-23","resultsPosted":"2013-10-29","lastUpdate":"2018-02-15"},"enrollment":503,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Fluticasone Furoate/GW642444","otherNames":[]},{"type":"DRUG","name":"Fluticasone propionate","otherNames":[]}],"arms":[{"label":"Fluticasone furoate/GW642444","type":"EXPERIMENTAL"},{"label":"Fluticasone propionate","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the long-term safety of fluticasone furoate/GW642444","primaryOutcome":{"measure":"Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During the Treatment Period","timeFrame":"From the start of study medication until Visit 11 (Week 52)/Early Withdrawal","effectByArm":[{"arm":"FF/VI 100/25 µg OD","deltaMin":139,"sd":null},{"arm":"FF/VI 200/25 µg OD","deltaMin":134,"sd":null},{"arm":"FP 500 µg BID","deltaMin":73,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":47,"countries":["United States","Germany","Thailand","Ukraine"]},"refs":{"pmids":["23440247","36472162"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":201},"commonTop":["Headache","Upper respiratory tract infection","Nasopharyngitis","Cough","Oropharyngeal pain"]}}